Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction

Supportive Care in Cancer

Volumn 20, Issue 9, 2012, Pages 1991-1997

  Berger, Michael J ^c   Dunlea, Leslie J ^a   Rettig, Amy E ^a   Lustberg, Maryam B ^a   Phillips, Gary S ^b   Shapiro, Charles L ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Abbreviated; Hypersensitivity; Paclitaxel; Premedication; Prophylaxis

Indexed keywords

ADRENALIN; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; GEMCITABINE; HYDROCORTISONE; METHYLPREDNISOLONE; PACLITAXEL; PLACEBO; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; AGED; ANGIONEUROTIC EDEMA; ANXIETY; ARTICLE; BACKACHE; BREAST CANCER; BRONCHOSPASM; CANCER CHEMOTHERAPY; DIAPHORESIS; DRUG ERUPTION; DRUG INFUSION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLUSHING; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; INFLAMMATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REPEATED DRUG DOSE; TACHYCARDIA; THORAX PAIN; URTICARIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DEXAMETHASONE; DRUG HYPERSENSITIVITY; FEASIBILITY STUDIES; FEMALE; FOCUS GROUPS; GLUCOCORTICOIDS; HISTAMINE ANTAGONISTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PACLITAXEL; PREMEDICATION; UNITED STATES; WITHHOLDING TREATMENT;

EID: 84865174174     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1303-9     Document Type: Article

References (17)

1. Sparano JA et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663-1671 (Pubitemid 351549913)
2. Seidman AS et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26(10):1642-1649
3. ® injection (package insert). Princeton, NJ: Bristol-Myers Squibb Company; July 2007
4. Miller K et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (26):2666-2676
5. Markman M et al (1999) An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 125(7):427-429 (Pubitemid 29287502)
6. Bookman MA et al (1997) Intravenous prophylaxis for paclitaxelrelated hypersensitivity reactions. Semin Oncol 24(6 Suppl 19):S19-13-S19-15
7. Kloover JS et al (2004) Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of pre-medication regimens. Br J Cancer 90:304-305 (Pubitemid 38250619)
8. Micromedex. Diphenhydramine. v 1.0 2007. http://www.thomsonhc.com/ micromedex2/librarian. Accessed March 2007
9. Quock J et al (2002) Premedication strategy for weekly paclitaxel. Cancer Invest 20(5-6):666-672 (Pubitemid 37210037)
10. Koppler H et al (2001) Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. Onkologie 24(3):283-285, English, German (Pubitemid 32664560)
11. Braverman AS et al (2005) Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration. Chemotherapy 51(2-3):116-119, Epub 2005 May 9 (Pubitemid 40981068)
12. Lenz HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12(5):601-609
13. Markman M et al (2000) Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 18(1):102-105 (Pubitemid 30036342)
14. Zanotti KM, Markman M (2001) Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 24 (10):767-779 (Pubitemid 32848355)
15. Gradishar WJ et al (2005) Phase III trial of nanoparticle albuminbound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 (31):7794-7803 (Pubitemid 46657376)
16. Sumikawa Tet al (2008) Dexamethasone interferes with trastuzumabinduced cell growth inhibition through restoration of AKT activity in BT-474 breast cancer cells. Int J Oncol 32(3):683-688
17. Morita M et al (2007) Dexamethasone inhibits paclitaxelinduced cytotoxic activity through retinoblastoma protein dephosphorylation in non-small cell lung cancer cells. Int J Oncol 30(1):187-192